Tonix Pharmaceuticals Announces Transition To Fully Integrated Biopharmaceutical Company Expected On April 1, 2024
Tonix Pharmaceuticals Announces Transition To Fully Integrated Biopharmaceutical Company Expected On April 1, 2024
Zembrace SymTouch and Tosymra will be marketed by Tonix Medicines, Tonix's wholly-owned commercial subsidiary
Zembrace SymTouch 和 Tosymra 將由 Tonix 的全資商業子公司 Tonix Medicines 銷售
Commercial capabilities prepare Tonix for the potential launch in 2025 of Tonmya for the management of fibromyalgia, assuming FDA approval
假設美國食品藥品管理局批准，商業能力使Tonix爲可能於2025年推出用於治療纖維肌痛的Tonmya做好準備
CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024. Since the acquisition of Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals has been putting in place the personnel, systems and contracts required to support a commercial organization. Both products are indicated for the treatment of acute migraine with or without aura in adults.
新澤西州查塔姆，2024年3月19日（GLOBE NEWSWIRE）——擁有上市產品和候選開發渠道的生物製藥公司Tonix Pharmicals Holding Corp.（納斯達克股票代碼：TNXP）（Tonix或公司）今天宣佈，它將在2024年4月1日實現向完全整合的製藥公司過渡的目標。自2023年6月30日收購Zembrace SymTouch（舒馬曲坦注射液）3毫克和Tosymra（舒馬曲坦鼻腔噴霧劑）10毫克以來，Tonix Pharmicals一直在提供支持商業組織所需的人員、系統和合同。兩種產品均適用於治療成人有或無先兆的急性偏頭痛。
"Tonix will become a fully integrated biopharmaceutical company with a mission of developing and marketing innovative, high-value therapeutics," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Tonix will assume responsibility for the distribution, selling and marketing of Zembrace SymTouch and Tosymra, as well as supply chain, regulatory and quality control of the two products."
Tonix Pharmicals首席執行官塞思·萊德曼醫學博士表示：“Tonix將成爲一家完全整合的生物製藥公司，其使命是開發和銷售創新的高價值療法。”“Tonix將負責Zembrace SymTouch和Tosymra的分銷、銷售和營銷，以及這兩種產品的供應鏈、監管和質量控制。”
Dr. Lederman added, "The assumption of commercial activities by Tonix represents an important milestone in the evolution of Tonix as we continue to build and strengthen our commercial organization for the potential launch of Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in 2025, assuming approval by the U.S. Food and Drug Administration (FDA)."
萊德曼博士補充說：“假設獲得美國食品藥品監督管理局（FDA）批准，Tonix對商業活動的假設是Tonix演變中的一個重要里程碑，因爲我們將繼續建立和加強我們的商業組織，以期在2025年推出治療纖維肌痛的Tonmya（鹽酸環苯扎林舌下片劑）。”
譯文內容由第三人軟體翻譯。